For example, a male patient with NSCLC receiving ICI therapy who presented with a WBC = 9, β2-MG = 4, GLB = 33, CD4/CD8 ratio = 2, PLR = 176, and NLR = 5 would have an estimated IMC risk of 0.009 (95% CI: 0.004–0.019). This evidence concerns the gene CD8A and non-small cell lung carcinoma.